Svennilson Peter
Follow13F filer, CIK 1606074, SAN FRANCISCO, CA
Svennilson Peter reported $789,930,000 across 6 holdings for the quarter ended 2020-03-31, in a 13F-HR filed 2020-05-07.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001606074-20-000005
- Period
- 2020-03-31
- Reported value
- $790M
- Holdings
- 6
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 0
Stakes and trades reported after 2020-03-31
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
Accepted , ingested - TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| RVMDnew | +7,977,384 | $175M |
| NGM BIOPHARMACEUTICALS INCadded | +902,315 | $11.1M |
| CONSTELLATION PHARMACEUTICALadded | +41,674 | $1.31M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
None.
Holdings, Q1 2020
Share positions as resolved from 13F-HR 0001606074-20-000005, largest first. % of portfolio is the value over $789,930,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 17,323,144 | $214M | 27.04% | +902,315 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 6,051,376 | $190M | 24.08% | +41,674 | |||
| RVMDREVOLUTION MEDICINES INC | 7,977,384 | $175M | 22.13% | new | Timeline | ||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 6,777,151 | $144M | 18.25% | 0 | |||
| RCUSARCUS BIOSCIENCES INC | 3,540,850 | $49.1M | 6.22% | 0 | Timeline | ||
| GRITSTONE BIO INCGRITSTONE BIO INC | 3,102,934 | $18.1M | 2.29% | 0 |
How Q1 2020 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001606074-20-000005 | base | 2020-05-07 | acceptance time not in the bulk data set |